About Mounjaro®
Class: Brand tirzepatide for T2D
Brand/Manufacturer: Eli Lilly
Dosing: Weekly subcutaneous (2.5-15 mg)
Mean weight loss: See SURPASS
Pivotal trial: SURPASS-1 through SURPASS-5
Mounjaro® is Eli Lilly's brand-name tirzepatide approved for type 2 diabetes. Off-label use for weight loss common before Zepbound launch. SURPASS-2 showed superior glycemic control vs semaglutide. Retail $999/month without insurance.
Mechanism of action
Mounjaro® acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is See SURPASS body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Mounjaro®'s weight management indication is SURPASS-1 through SURPASS-5. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Mounjaro® via telehealth
Mounjaro® is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Mounjaro® access — see the side panel for details.
FAQ
Is Mounjaro® FDA-approved?
The brand-name versions of Mounjaro® are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Mounjaro® cost?
Brand-name Mounjaro® typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.